Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real‐world retrospective study and literature review

• Published in: Dermatologic therapy Vol. 35; no. 12; pp. e15950 - n/a
• Main Authors: Cheng, Pai‐Shan, Hou, Ping‐Chen, Yang, Chao‐Chun, Chu, Chia‐Bao
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-12-2022
• Subjects: Antibodies, Monoclonal - therapeutic use; body region; Humans; psoriasis; Psoriasis - chemically induced; Psoriasis - diagnosis; Psoriasis - drug therapy; real‐world; Retrospective Studies; Secukinumab; Severity of Illness Index; Treatment Outcome; Ustekinumab; Ustekinumab - adverse effects; Ustekinumab; real-world; Secukinumab; psoriasis; body region
• ISSN: 1396-0296; 1529-8019
• DOI: 10.1111/dth.15950

Psoriasis in different body regions displays varying therapeutic responses to biologics, whereas currently relevant studies remain scarce. We retrospectively reviewed the treatment responses of patients with moderate‐to‐severe psoriasis, who completed the two‐year reimbursed ustekinumab or secukinumab treatment in two medical centers in Southern Taiwan. Demographic profiles and body regional PASI scores (head/neck, trunk, upper and lower limbs) along the treatment course were recorded. The proportions of patients attaining PASI 75, 90, 100 and the extent of body regional PASI score improvements were compared in biologic naïve or experienced patients. A total of 57 and 67 patients receiving ustekinumab and secukinumab injections, respectively, were included. Overall, patients receiving secukinumab showed higher degrees of PASI score improvements along the two‐year treatment course. The lower limbs had the highest, and the upper extremities and head/neck had the lowest post‐treatment PASI scores regardless of prior biologic use in the groups of ustekinumab and secukinumab. The upper limbs showed the highest, while the lower limbs had the lowest complete remission rate (regional specific PASI 100) in response to ustekinumab (upper limbs 48.7%, lower limbs 25.6%) and secukinumab (upper limbs 77.1%, lower limbs 42.8%) in biologic naïve groups. Our study demonstrated that lower limbs were the most treatment‐refractory area in response to ustekinumab and secukinumab injections, while the upper limbs and head/neck region had a better response.